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The vascular smooth muscle cell (SMC)-speciﬁc isoform of a-actin (ACTA2) is a major component of the contractile apparatus in SMCs
located throughout the arterial system. HeterozygousACTA2mutations cause familial thoracic aortic aneurysms and dissections (TAAD),
but only half of mutation carriers have aortic disease. Linkage analysis and association studies of individuals in 20 families with ACTA2
mutations indicate that mutation carriers can have a diversity of vascular diseases, including premature onset of coronary artery disease
(CAD) and premature ischemic strokes (including Moyamoya disease [MMD]), as well as previously deﬁned TAAD. Sequencing of DNA
from patients with nonfamilial TAAD and from premature-onset CAD patients independently identiﬁed ACTA2 mutations in these
patients and premature onset strokes in family members with ACTA2 mutations. Vascular pathology and analysis of explanted SMCs
and myoﬁbroblasts from patients harboring ACTA2 suggested that increased proliferation of SMCs contributed to occlusive diseases.
These results indicate that heterozygous ACTA2 mutations predispose patients to a variety of diffuse and diverse vascular diseases,
including TAAD, premature CAD, ischemic strokes, and MMD. These data demonstrate that diffuse vascular diseases resulting from
either occluded or enlarged arteries can be caused by mutations in a single gene and have direct implications for clinical management
and research on familial vascular diseases.Introduction
Mutations in genes inherited in a Mendelian manner and
leading to adult-onset disorders have been identiﬁed for
many diseases, including breast and colon cancer, as well
as hypertrophic and dilated cardiomyopathy. In contrast,
the identiﬁcation of single genes that lead to premature
onset of coronary artery disease (CAD) in the absence of
abnormal lipoprotein levels has been limited to only a few
genes.1,2 Furthermore, no single-gene disorders have been
shown tocause large-vessel ischemic strokes. The slowprog-
ress made in identifying vascular disease genes is felt to be
due to signiﬁcant genetic heterogeneity for these diseases,
along with the complex interactions between genes and
environmental factors that contribute to the disease patho-
genesis, including smoking, diabetes mellitus, obesity, and
systolic blood pressure.3 Another factor potentially delay-
ing the progress of gene identiﬁcation for vascular diseases
is that genes encoding proteins required for vascular SMC
function and arterial-wall structure are expressed in arteries
throughout the body, and mutations in these genes could
lead to diffuse vascular diseases involving many arteries.Therefore, mapping strategies focused on a restricted
vascular phenotype, such as ischemic stroke or aortic
aneurysm, may delay the identiﬁcation of disease genes.
Supporting this hypothesis are the diffuse vasculopathies
associated with many genetic syndromes caused by
single-gene mutations, including vascular Ehlers-Danlos
syndrome (EDS VI [MIM 225400]) and neuroﬁbromatosis
1 (NF1 [MIM 162200]).4,5 The NF1 vasculopathy not only
affects many different arteries but can present as either
enlargement or occlusion of arteries. These facts raise the
question of whether vascular-disease genes could be identi-
ﬁed more rapidly if mapping and identiﬁcation focused on
premature onset of vascular disease in families irrespective
of the vascular bed affected.
The major function of vascular smooth muscle cells
(SMCs) is to contract in response to the stretch resulting
from pulsatile blood ﬂow, a process that is dependent on
the cyclic interaction between thin ﬁlaments, composed
of the SMC-speciﬁc isoformof a-actin (SM a-actin, encoded
by ACTA2), and thick ﬁlaments, composed of SMC-speciﬁc
b-myosin. The importance of SM a-actin for SMC function
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expression characterizes SMC differentiation and is the
single most abundant protein in differentiated SMCs,
accounting for ~40% of the total cellular protein and
~70% of the total actin.6,7 Second, Acta2 null mice ex-
hibited normal cardiovascular development but compro-
mised vascular contractility, tone, and blood ﬂow.8,9
Finally, heterozygous mutations in ACTA2 in humans
lead to an inherited predisposition for thoracic aortic aneu-
rysms and dissections (TAAD). ACTA2missense mutations
are the major genetic cause of familial TAAD identiﬁed to
date and are responsible for disease in 15% of families.10
Interestingly, in these families, only half of ACTA2 muta-
tion carriers have aortic disease, a penetrance lower than
that typically observed for genes leading to familial TAAD.
We noted that all ACTA2-mutation carriers in a large
family had marked and persistent livedo reticularis (LR),
a purplish reticular rash caused by occlusion of the dermal
arteries.10 InACTA2-mutant aortas, occlusionof the arteries
in the vasa vasorum as a result of increased SMCs in the
vessel wall was also noted. These observations raised the
possibility that ACTA2 mutations could also result in
vascular occlusion. To test this hypothesis, we assessed
our familieswithACTA2mutations for the premature onset
of vascular diseases, including coronary artery disease,
ischemic strokes, and transient ischemic attacks (TIAs),
before the age of 55 years in men and before age 60 years
in women. Both linkage and association data from these
families support the conclusion that ACTA2 mutations
lead to vascular occlusive diseases. Furthermore, we found
that explanted SMCs and myoﬁbroblasts harboring
ACTA2 mutations proliferate more rapidly than control
cells, suggesting that ACTA2 mutations lead to occlusive
disease through increased proliferation of SMCs. These
data support the conclusion that a single-gene mutation
can cause a diffuse and diverse vasculopathy.
Subjects and Methods
Family Characterization and Sample Collection
The institutional review board at the University of Texas Health
Science Center at Houston (UTHSCH) approved this study. Fami-
lies with multiple members with TAAD and no known genetic
syndrome were recruited and characterized as previously
described.11 Family members at risk for TAAD were imaged for
the presence of asymptomatic ascending aortic aneurysms. Indi-
viduals were considered affected if they had dissection of the aorta,
surgical repair of an ascending aortic aneurysm, or dilatation of
the ascending aorta greater than two standard deviations as
compared to the normal diameter of the aortic segment.12 These
measurements were based on echocardiography images of the
aortic diameter at the sinuses of Valsalva, the supra-aortic ridge,
and the ascending aorta compared in healthy and affected individ-
uals. Premature CAD and stroke are designated in this study as
onset of the disease at the age of 55 years or younger in men
and 60 years or younger in women. Medical records pertaining
to vascular diseases and risk factors were collected of all family
members for veriﬁcation of diagnoses regardless of mutation-
carrier status. The diagnosis of CAD is based on documentation618 The American Journal of Human Genetics 84, 617–627, May 15of a myocardial infarct or 70% narrowing of one or more coronary
arteries noted during either cardiac catheterization or cardiac
pathology performed at the time of autopsy. Ischemic strokes
were diagnosed on the basis of the presence of cerebral infarct in
cerebral imaging or diagnosis of a transient ischemic attack
(TIA). Diagnosis of Moyamoya disease (MMD) is based on cerebro-
vascular imaging demonstrating stenosis or occlusion of the
terminal portion of the internal carotid artery, the formation of
an abnormal vascular network in the vicinity of the arterial occlu-
sion, and review of the patient’s history and images for exclusion
of other causes of stenosis, such as atherosclerosis.
Blood or buccal cells were collected for DNA. Mutation status of
family members was determined by sequencing of their DNA or
inferred by their location in the pedigree (e.g., their parent and
offspring were documented to have the mutation). Individuals
who were at 50% risk for inheriting a mutation and died of an
aortic dissection were assumed to have the mutant gene because
dissection is an uncommon vascular event, whereas at-risk indi-
viduals who died of stroke or CAD were not assumed to carry
the mutation because of the frequency of these conditions in
the population. Control DNA was obtained from whites, African
Americans, Filipinos, and Hispanics who did not have cardiovas-
cular disease.
TexGen Patient Sample Collection
Patients admitted to Texas Medical Center (TMC) hospitals were
recruited for the study. With the patients’ consent, samples and
clinical data were collected, de-identiﬁed, and banked as part of
TexGen Research. TexGen is a collaborative genetic-discovery
research project within the TMC and includes The UTHSCH,
The University of Texas M.D. Anderson Cancer Center, Baylor
College of Medicine and their afﬁliated hospitals, and the Texas
Heart Institute. Patients with strokes and TIAs were recruited at
Memorial Hermann Hospital. Patients admitted for chest pain
due to coronary artery disease were recruited for TexGen at the
Texas Heart Institute at St. Luke’s Episcopal Hospital and theMeth-
odist Hospital. General health information, cardiovascular risk
factors, clinical diagnosis, and treatment of patients were obtained
from the patient or extracted from the medical records and
recorded in the TexGen database.
Sequencing Protocol
Bidirectional sequencing of ACTA2 exons was done at the Human
Genome Sequencing Center at Baylor College of Medicine with
the use of intron-based, exon-speciﬁc primers. PCR ampliﬁcations
were carried out with HotStar Taq DNA polymerase (QIAGEN,
Valencia, CA). PCR products were treated with Exo_SAP (USB,
Cleveland, OH) for digestion of primers, followed by sequencing
PCR with the BigDye sequencing reaction mix (Applied Biosys-
tems, Foster City, CA). The sequencing PCR products were puriﬁed
via the BigDye XTerminator kit (Applied Biosystems) and then
loaded on an ABI3730xl sequencing instrument with the Rapid36
run module. The DNA sequencing results were analyzed with SNP
Detector software.13 Identiﬁed mutations were veriﬁed by bidirec-
tional resequencing of the original DNA sample in another lab
(D.M.M.’s lab).
Statistical Analysis
Two-point linkage analysis with ACTA2-mutation status was
performed with TAAD and the combined phenotype of TAAD,
CAD, and stroke or combinations of these phenotypes. The, 2009
disease-allele frequencyandpenetranceofCADand strokewere the
same as those deﬁned for TAAD, and 0.001 was the minor allele
frequency of the ACTA2 mutation.14 Association of ACTA2 muta-
tions with CAD and stroke was performed via Fisher’s exact test as
implemented in the software StatXact (Cytel Statistical Software
and Services). Pairwise LOD scores were calculatedwith theMLINK
program of the computer software FASTLINK, version 3.P.15
Structural Analyses
The atomic coordinates of actin (Protein Data Bank [PDB] ID: 1J6Z)
were obtained from the PDB. Structure superposition and visuali-
zation were performed with O.16 Nonbonded and hydrogen-
bonded contacts were determined with HBPLUS.17 Figures were
generated with PyMOL.18
Pathology and Cell-Proliferation Assays
Formalin-ﬁxed, parafﬁn-embedded tissue sections from patient
and control aortas and coronary arteries and myocardium from
two deceased patients were stained with H&E and Movat. Addi-
tional tissue sections were immunostained with monoclonal anti-
body for SM a-actin obtained from Sigma.10
SMCs were explanted from the ascending thoracic aorta above
the sinuses of Valsalva, from two patients with ACTA2 mutations
and two controls, and subcultured in SmBm containing 15% FBS
(Table S1, available online).19 Cells at passage 2 were plated in trip-
licate at 10,000 cells per well in a 96-well plate. After 24 hr, the
cells were placed in media containing 0.2% FBS and incubated
with BrdU reagent for 24 hr for quantiﬁcation of cell proliferation.
Cells were ﬁxed, and an ELISA for BrdU was carried out according
to the manufacturer’s instructions (Millipore). A Student’s t test
was used in determining whether the increase in cell proliferation
was statistically signiﬁcant. Data are represented with the standard
error of the mean indicated.
Dermal ﬁbroblastswere explanted frompatientsheterozygous for
anACTA2mutation and fromcontrolswithout vascular disease and
were subcultured in DMEM containing 10% FBS (Table S1). Cells
from passages 2 or 3 were plated in triplicate at a density of 20,000
cells per well and placed in DMEM containing 0.2% FBS. After
24 hr, fresh DMEM containing 0.2% FBS with and without 10 ng/
mL TGF-b1 was added to the cells. Cells were incubated for 72 hr
after TGF-b1 treatment, followed by 24 hr of incubation with
BrdU reagent. Cells were ﬁxed, and an ELISA for BrdU was done.
Statistical analysis was performed as described for the SMCs. Data
were tested for normal distribution via a D’Agostino-Pearson test.
Data are represented with the standard error of the mean indicated
and are a composite of three independent experiments. For conﬁr-
mation that ﬁbroblasts transformed to myoﬁbroblasts with
TGF-b1 exposure, cells were treated with and without TGF-b1, har-
vested, and lysed inRIPAbuffer. Equal amounts of total proteinwere
separated through gel electrophoresis, transferred to a PVDF
membrane, and immunoblotted with antibodies directed against
SM a-actin and GAPDH (Abcam) for conﬁrmation of increased
expression of SM a-actin 72 hr after exposure to TGF-b1.20,21
Results
Assessment of Vascular Diseases in Families
with ACTA2 Mutations
Twenty families, with 127 members harboring heterozy-
gous ACTA2 mutations, were phenotyped for prematureThe Amvascular diseases, deﬁned as an age at onset less than 55
years in men and less than 60 years in women (Table S2).
Family members age 21 years and older were included,
along with members who presented with vascular diseases
at younger ages. The thoracic aortic disease was previously
reported in 14 of these families.10 Six additional families
with ACTA2 mutations are included in the present study
(c.215C/A; p.P72Q in TAA018, c.479G/A; p.G160D in
TAA200, c.116G/A; p.R39H in TAA252 and TAA331,
c.353G/GA; R118Q in TAA441, and c.554G/A;
p.R185Q in TAA455 [Figure 1 and Figure S1]). Mutations
were conﬁrmed by exclusion of the alteration in 192 ethni-
cally matched controls and segregation of the alterations
with aortic disease in the families. Note that bidirectional
sequencing of the exons and ﬂanking introns of ACTA2
in 192 white controls identiﬁed no variants.
TAAD was the primary vascular disease in ACTA2-muta-
tion carriers (76 individuals), but carriers also had prema-
ture onset of CAD (26 individuals) and ischemic strokes
(15 individuals); 15 individuals had more than one
vascular disease (Figure 1A). In contrast, none of the family
members without an ACTA2 mutation had TAAD, prema-
ture CAD, or stroke in these families. Five families had
multiple ACTA2-mutation carriers with CAD (TAA252,
327, 370, 441, and 445), including two families with the
recurrent ACTA2 c.445C/T; p.R149C mutation previ-
ously shown not to be related.10 One family (TAA455)
had more ACTA2-mutation carriers with premature CAD
than with aortic disease. It is important to note that
neither coronary occlusion nor stroke was caused by aortic
dissection or aortic surgical repair in these family
members.
Although premature ischemic strokes also occurred in
ACTA2-mutation carriers in these families, very early onset
strokes occurring under the age of 20 were noted in four
families (TAA105, 252, 377, and 390 [Figures 1A and
1B]). Three of these families had an ACTA2 mutation
altering arginine 258 (c.772C/T; p.R258C and c.773G/
A; p.R258H), and in these families, 10 out of 14 mutation
carriers had aortic disease and seven had onset of strokes
at ages ranging from 5 to 46 years of age. Five of seven
acute strokes were classiﬁed as MMD, a rare cerebral arte-
riopathy caused by occlusion of the supraclinoid portion
of the internal carotid arteries as a result of ﬁbrocellular
proliferation in the arteries (Figure S2A). The other two
individuals, TAA377:II:1 and III:2, had strokes at ages 32
and 17 years, respectively, but imaging records could not
be obtained. Recent imaging studies identiﬁed fusiform
cerebral aneurysms in both individuals (current ages 53
and 27 years [Figure S2B]).
Linkage analysis and penetrance of the various vascular
diseases in all of the ACTA2-mutation families were
analyzed. The LOD score for TAAD in the 20 ACTA2-muta-
tion families was 6.7, with a calculated penetrance for
TAAD between the ages of 40 and 60 years of 0.48 (Table
S3). Evidence thatACTA2mutations also caused premature
occlusive vascular disease in these families was supportederican Journal of Human Genetics 84, 617–627, May 15, 2009 619
Figure 1. Vascular Diseases in Families with ACTA2 Mutations
(A) Pedigrees of 12 families with ACTA2 mutations in which the mutation segregates with a number of vascular diseases, including TAAD,
premature onset of CAD, and stroke. The disease and mutation status of individuals are as indicated in the figure legend.
(B) Three families with ACTA2 R258 mutations with early age at onset of stroke and MMD.
(C) Pedigrees of patients with ACTA2 mutations identified from Texgen cohort. Pedigrees of two patients with nonfamilial TAAD and de
novo ACTA2 mutations and of one patient with nonfamilial TAAD, a sister with MMD, and a mother with premature CAD due to an ACTA2
mutation. Numbers and letters under each circle or square in the pedigree represent the following: the first line shows the individual ID
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by positive LOD scores for premature CAD, stroke, and
combined CAD and stroke vascular phenotypes: 2.49,
1.65, and 3.93, respectively. Because we speciﬁcally tested
the role of ACTA2 mutation in premature CAD, stroke,
and combined CAD and stroke vascular phenotypes, the
p values associated with these LOD scores were highly
signiﬁcant (0.0004, 0.0029, and 1.063 105, respectively).
The calculated penetrance of ACTA2 mutation for prema-
ture CAD and stroke between the ages of 40 and 60 years
is 0.30 and 0.15, respectively. The LOD score for all
vascular diseases combined—TAAD, premature CAD, and
stroke—rose to 10.62 for the families, associated with a
corresponding increase of the penetrance between 40
and 60 years to 0.80, further supporting our hypothesis
that ACTA2 mutations lead to occlusive diseases.
As a control for other genetic and environmental factors
predisposing family members to premature CAD and
strokes, the number of family members with ACTA2muta-
tions and premature onset of CAD or strokes (40 individ-
uals out of 127 carriers) was compared with the number
of family members who had these premature vascular
diseases but did not have an ACTA2 mutation (0 out of
104 family members) (p ¼ 1.7 3 1012). Thus, in these
families, individuals with ACTA2 mutations are signiﬁ-
cantly more likely to have premature CAD and stroke
compared with family members without ACTA2 muta-
tions. These data support the hypothesis that ACTA2
mutations lead to premature stroke and CAD, in addition
to the previously established predisposition to TAAD.
ACTA2 Mutations in Patients with Thoracic Aortic
Disease and Premature Onset of Coronary Artery
Disease and Stroke
We sought to determine the frequency of ACTA2 muta-
tions in patients with nonfamilial TAAD. The nine exons
and ﬂanking intronic regions of ACTA2 were sequenced
in 237 patients who were admitted for surgical repair of
a thoracic aortic aneurysm or acute aortic dissection and
did not have a family history of aortic disease (Table 1).
Heterozygous ACTA2 mutations were identiﬁed in ﬁve
white men and one woman (2.5%), and these alterations
were not present in 192 white controls. Three of these
men had ischemic strokes at ages 22, 26, and 41 years prior
to presenting with an acute aortic dissection at ages 27, 26
and 42 years, respectively (2340, 6375, and 5875 [Table
S4]). Two men were conﬁrmed to have de novo mutations;
the mutation was not present in the parental DNA, and
paternity was conﬁrmed through analysis of polymorphic
microsatellite markers (Figure 1C). The sister and mother
of patient 8622 were found to be heterozygous for the
ACTA2 c.635G/A; p.R212Qmutation. His sister was diag-nosed with MMDwhen she presented with an acute stroke
at the age of 17 years, and his mother presented with CAD
requiring stent placement at the age of 55 years (Figure 1C).
Patient 9025 had a heterozygous ACTA2 alteration
(c.977/A; p.T326N) and had an ascending aortic aneu-
rysm and bicuspid aortic valve diagnosed at the age of
59 years. Her son carried the alteration and had a stroke
at the age of 25 years. Her daughter, age 57 years, also
harbored the mutation and has declined aortic imaging.
The identiﬁcation of premature strokes due to ACTA2
mutations in nonfamilial TAAD patients, along with the
segregation of premature occlusive disease (stroke and
CAD) in family members, further supports the conclusion
that ACTA2 mutations lead to occlusive diseases.
For determination of the contribution of ACTA2 muta-
tions to premature strokes and CAD, genomic DNA
collected from TexGen patients with these vascular
diseases was sequenced for ACTA2 mutations. DNA was
sequenced from 216 patients with CAD and 271 patients
with acute strokes or TIAs who were age 55 years or
younger (men) or 60 years or younger (women) (Table 2).
Although primarily ischemic strokes were observed in
families with ACTA2 mutations, fusiform aneurysms
were documented in two family members, and MMD can
present with either ischemic or hemorrhagic strokes.
Table 1. Texgen Patients with Sporadic Thoracic Aortic
Aneurysm and Dissection Patients
Clinical Data No. (%)
Ascending aneurysma 182 (76)
Ascending dissection 40 (17)
Descending aneurysm 56 (24)
Descending dissection 25 (11)
Mean Age (yrs) 61 5 14; range 16–86
Male 155 (65)
Female 83 (35)
White 200 (84)
African-American 19 (8)
Hispanic 9 (4)
Native American 1 (< 1)
Other ethnicity 9 (4)
BMI 28 5 6 (range, 10 - 52)
Hypertension 170 (72)
Diabetes 23 (10)
Current smoker 46 (19)
Past smoker 107 (45)
Never smoked 84 (35)
BAV 25 (10)
CAD: Male, age < 55 7 (3)
CAD: Female, age < 60 1 (<1)
Stroke 11 (5)
n ¼ 237.
a A subset of patients had more than one type of thoracic aortic disease.number; the second line shows age at onset of the vascular disease(s), which is color coded based on the vascular disease (see the figure
legend); and an asterisk next to a symbol indicates that individuals had MMD. Individuals in (C) are labeled with their sample ID number.
Circles represent females, and squares represent males. A slash through a circle or square indicates a deceased person. A pound sign (#)
indicates an individual who may have carried the ACTA2 mutation, on the basis of their location in the pedigree, but was not assumed to
harbor a mutation in the genetic and clinical analysis of ACTA2-mutation carriers.
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Table 2. Texgen Patients with Premature Coronary Artery Disease and Stroke
Clinical Data No.: CAD (%) No.: Stroke (%)
TIA 22 (8)
Infarct 158 (58)
Intracranial hemorrhage 78 (29)
Unknown 13 (5)
Mean Age (yrs) 48 5 6; range 25–60 555 8; range 17–60
Male 151 (70) 165 (61)
Female 65 (30) 106 (39)
White 138 (64) 111 (41)
African-American 34 (16) 108 (40)
Hispanic 35 (16) 46 (17)
Asian 9 (4) 4 (1)
Other 0 (0) 2 (1)
BMI 30.985 7.5; range 15.64–49.81 25.985 4.19; range 20.12–9.93
Hypertension 150 (69) 171 (63)
Diabetes 139 (64) 61 (23)
Smoking history (present and past) 64 (30) 238 (88)
Family history: father 107 (50) 36 (13)
Family history: mother 60 (28) 54 (20)
Family history: siblings 49 (23) 29 (11)
Cholesterol (mg/dl) 182.195 80.00 187.905 50.88
HDL (mg/dl) 38.155 12.71 41.845 16.30
LDL (mg/dl) 108.895 76.89 118.775 40.80
Triglyceride (mg/dl) 92.875 195.02 147.665 125.85
n ¼ 216 CAD patients, 271 stroke patients.Therefore, patients with both ischemic and hemorrhagic
strokes were included for mutational analysis. A missense
mutation in ACTA2 (p.T326N) was identiﬁed in a 53-
year-old man of Northern European descent who pre-
sented with an anterior myocardial infarct due to left ante-
rior descending stenosis (TS2088 [Table S4]). The patient’s
family declined to be studied. No ACTA2 mutations
conﬁrmed to disrupt protein structure were identiﬁed in
patients with premature strokes. Two unique ACTA2 alter-
ations leading to synonymous changes in the amino acid
were noted in the coding region of a 45-year-old African
American man with CAD and a 51-year-old of Northern
European descent with an ischemic stroke (c.417G/A
and c.936C/T, respectively) and were not present in
matched controls. The biological and clinical signiﬁcance
of these alterations is not known.
Genotypes Associated with Vascular Phenotypes
Analysis of themutated sites along the SM a-actin sequence
suggests that different vascular diseases are associated with
speciﬁc ACTA2 missense mutations (Figure 2). Assessment
of mutations with greater than 15 carriers (p.R118Q,
p.R149C, p.R258C, andp.R258H) indicates that p.R258C/H
mutations are associated primarily with strokes, including
those with an age at onset less than 20 years, and not with
CAD, whereas p.R118Q and p.R149C lead primarily to
CAD and are less frequently associated with strokes
(Figure 2A). Of the individuals with either the p.R118Q or
the p.R149C mutation, 18 (30%) had CAD and 42 (70%)
did not. In comparison, in individuals with other ACTA2
mutations, 8 (11.9%) had CAD and 59 (88.1%) did not.
On the basis of a Fisher’s exact test, these two mutations622 The American Journal of Human Genetics 84, 617–627, May 15predispose one to CAD at a 3.1-fold increased risk (conﬁ-
dence interval [CI]:1.16–9.15, p value ¼ 0.01) compared
with other ACTA2 mutations. A similar analysis of the
p.R258C/Hmutations indicates that thesemutations result
in a 6.51-fold increased risk of stroke (CI:1.71–24.72,
p value ¼ 0.02).
The p.R258C/H mutations lie within the SM a-actin SD4
domain (Figure 2B). This domain participates in the
opening and closing of the nucleotide binding cleft.
Notably, p.R212Q, which also causes MMD, also resides
in this domain. Furthermore, an additional mutation
causing stroke before the age of 20 years (p.R39H) is found
on the SD2 domain, whose dynamics are essential for ATP
hydrolysis. Conversely, the mutations leading primarily to
premature CAD (p.R149C and p.R118Q, along with
p.T353N) lie within the hydrophobic cleft of a-actin,
which serves as both the binding determinant of several
regulatory proteins and the target of diverse marinemacro-
lide toxins that permanently cap the barbed end and block
promoter addition or removal. It is important to note the
ACTA2 p.R185Q is found in a region that directly contacts
the nucleotide and, therefore, is more than likely to per-
turb ATP hydrolysis. On the basis of the ﬁve individuals
harboring this mutation, this alteration causes TAAD and
CAD and not stroke, so the perturbation of ATP hydrolysis
may not completely predict a predisposition to stroke.
Vascular Pathology and Increased Proliferation
of ACTA2-Mutant Cells
Available vascular tissues from patients harboring hetero-
zygous ACTA2 were obtained for a determination of
whether the vascular pathology would provide insight, 2009
Figure 2. Genotype-Phenotype Correlation between Location
of Mutation and Vascular Diseases
(A) Location of all ACTA2 mutations and the specific phenotypes
observed in patients heterozygous for those mutations. The muta-
tions are listed in sequential order and align with the exon in which
they are located. ‘‘No.’’ indicates the number of identified individ-
uals who carry each specific mutation. The headings TAAD, Stroke,
and CAD denote the number of individuals affected by each of
these conditions. An asterisk indicates a mutation leading to the
onset of ischemic strokes prior to the age of 20 years.
(B) The ribbon diagram of SM a-actin, identifying the location of
the different mutations at the protein-structure level. The recur-
rent ACTA2 mutation leading to ischemic strokes at a young age
(p.R258C/H, shown in green) lies within subdomain 4, whereas
mutations occurring in multiple individuals and leading primarily
to premature CAD (p.R149C and p.R118Q, shown in red) all lie
within the hydrophobic cleft.The Aminto the etiology of the occlusive vascular diseases in
affected individuals. Aortic samples from two patients
with ACTA2 mutations demonstrated increased diameter
and thickening of the walls of the vasa vasorum vessels
as compared to control aortas, a ﬁnding that had been
previously noted (data not shown).10 This thickening
was due to increased SMCs in the medial layer, ascertained
via immunostaining for SM a-actin. Despite the increased
outer diameter of the arteries, the lumen was stenotic or
occluded in some arteries.
We sought to determine whether the cardiac arteries in
ACTA2-mutation patients demonstrated similar prolifera-
tion of SMCs. Cardiac tissue was available from autopsies
of two ACTA2-mutation-positive members of family
TAA441. The coronary artery of a healthy 28-year-old
member (IV:3) who died of an acute aortic dissection
demonstrated signiﬁcant stenosis of the artery due to
intimal and medial ﬁbrocellular accumulation associated
with an atherosclerotic plaque (Figure 3A). The atheroscle-
rotic lesion was more cellular and had fewer lipids than
typical atherosclerotic plaques. The majority of the cells
in the lesion were SMCs, ascertained via SM a-actin stain-
ing (Figure 3A). In family member III:7, who died after
surgical repair of chronic descending aortic dissection,
the intracardiac arteries also had thickened walls due to
medial thickening (Figure 3B). Similar thickening of the
intracardiac arteries was noted at autopsy of TAA015:III:1.
The increased number of SMCs in the medial layers of
arteries suggested that the presence of an ACTA2missense
mutation leads to increased proliferation of SMCs. To test
this hypothesis, proliferation rates of SMCs and myoﬁbro-
blasts explanted from affected patients were compared
with age-, sex-, and passage-matched control cells (Table
S1). SMCs explanted fromACTA2-mutation patients prolif-
erated signiﬁcantly more rapidly in culture as compared
with control cells (p < 0.05 [Figure 3C]). Explanted ﬁbro-
blasts from dermal biopsies were available from nine
patients with ACTA2 mutations. Dermal ﬁbroblasts plated
in conﬂuent cultures express low levels of SM a-actin
and, with exposure to TGF-b1, are transformed into
myoﬁbroblasts expressing high levels of SM a-actin
(Figure 3D).20,21 Proliferation assays conﬁrmed that the
patients’ myoﬁbroblasts proliferated signiﬁcantly more
rapidly than controlmyoﬁbroblasts. The increased prolifer-
ation observed in SMCs with heterozygous ACTA2 muta-
tions and conﬁrmed through mutant myoﬁbroblasts
expressing SM a-actin may contribute to the increased
numbers of SMCs observed in vascular lesions in affected
individuals.
Discussion
Accumulating data from families harboring heterozygous
ACTA2 mutations support the conclusion that ACTA2
mutations predispose individuals to occlusive vascular
diseases, speciﬁcally premature CAD and strokes, inerican Journal of Human Genetics 84, 617–627, May 15, 2009 623
addition to the already established predisposition to TAAD.
The ﬁrst suggestion that ACTA2mutations cause occlusive
vascular lesions was the presence of livedo reticularis in
affected patients. Further evidence was provided by linkage
analysis of families with ACTA2mutations; the LOD score
and penetrance of the disease rose from 6.7 and 0.48 to
10.62 and 0.8 when TAAD was combined with premature
CAD and stroke. In addition, positive LOD scores were ob-
tained for premature CAD, stroke, and the combined CAD
and stroke phenotype, with a combined phenotype LOD
score of 3.93 (p ¼ 1.06 3 105). None of the 104 family
members without a mutation had premature CAD or
stroke, whereas 40 out of 127 ACTA2 carriers had prema-
ture onset of these vascular diseases, indicating a highly
signiﬁcant association of familial occlusive vascular
diseases with the mutation. Additional support was based
on the fact that none of the ACTA2-mutation-positive
Figure 3. ACTA2 Mutations Lead to
Increased SMC and Myofibroblast Prolif-
eration in Culture
(A) Coronary artery from 28-year-old
TAA441:IV:4, stained with Movat’s stain
and SM a-actin antibody. The coronary
artery showed 70% narrowing of the vessel
due to a fibrocellular atherosclerotic pla-
que (top two panels; magnification 403;
scale bar represents 1.0 mm). Higher
magnification (2003; scale bar represents
200 mm) revealed that these cells contain
SM a-actin.
(B) The epicardial arteries from a 50-year-
old man, TAA441:III:7, and a 53-year-old
woman, TAA015:III:1. H&E, Movat, and
a-actin immunostaining of the tissue
showed thickened vessels within the
myocardium (magnification 2003; scale
bar represents 200 mm).
(C) Cell-proliferation assays (BrdU incorpo-
ration) illustrate that SMCs explanted from
patients heterozygous for an ACTA2 muta-
tion (n ¼ 2) proliferate more rapidly than
matched control SMCs (n ¼ 2).
(D) Myofibroblasts (fibroblasts exposed to
TGF-b1 for 72 hr) from patients heterozy-
gous for ACTA2 mutations (n ¼ 9) prolif-
erate more rapidly than matched controls
(n ¼ 10). Data are expressed as means 5
SEM, and p values are indicated. Immuno-
blotting for SM a-actin from the cell
lysates confirms that TGF-b1 exposure
increased cellular SM a-actin.
members with premature occlusive
vascular disease had a major risk
factor for the early onset of these
vascular occlusive diseases, such as
plasma cholesterol levels consistent
with monogenic hypercholesterol-
emia (>280 mg/dl) or uncontrolled and severe hyperten-
sion, and only one individual had diabetes mellitus. A
nonfamilial TAAD patient with an ACTA2 mutation had
familymembers with the ACTA2mutations and premature
occlusive disease, and an ACTA2mutation was also identi-
ﬁed independent of TAAD in a man with premature CAD.
Finally, very early onset strokes and MMD (between the
ages of 5 and 44 years) occurred in members of three unre-
lated families who all harbored mutations altering R258 in
SM a-actin, a strong association supporting the idea that
ACTA2 mutations also lead to ischemic strokes.
The contribution of ACTA2 mutations to nonfamilial
vascular diseases was also assessed in this study. Only
2.5% of patients with sporadic TAAD had an ACTA2muta-
tion. The contribution of ACTA2 mutations to premature
CAD and stroke in the general population was even less,
with only one patient with CAD identiﬁed with an
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ACTA2mutation in the Texgen premature CAD and stroke
cohorts that were studied. Therefore, ACTA2 mutations
contribute to premature CAD and strokes in families
harboring ACTA2 mutations but appear to be a rare cause
of CAD and stroke in the general population.
Atherosclerosis, the underlying cause of CAD and
ischemic strokes, is associated with a number of risk
factors, including hypercholesterolemia, hypertension,
diabetes mellitus, and family history. The identiﬁcation
of genes predisposing one to occlusive arterial disease,
both private mutations linked to the disease and disease-
associated polymorphic variants, has identiﬁed four
distinct pathogenetic pathways: (1) hypercholesterolemia
leading to increased cholesterol deposition in the artery,
(2) loss of endothelial integrity, (3) factors promoting arte-
rial inﬂammation, and (4) factors increasing thrombosis in
vessels.22 Our data implicate a ﬁfth pathway for genetic
predisposition for occlusive arterial disease, in which
a mutant gene triggers inappropriate proliferation of
vascular SMCs, leading to stenosis of vessels. The fact
that SMCs and myoﬁbroblasts from affected individuals
proliferate more rapidly in culture than control cells
supports this pathway. Similar results were obtained in
the Acta2-deﬁcient mouse, in which increased prolifera-
tion of myoﬁbroblasts was noted both in vivo and
in vitro when compared with wild-type myoﬁbroblasts.23
Pathologic examination of affected aortic and cardiac
tissue showing enlarged and stenotic arteries with
increased SMCs primarily in the medial layer supports
the hypothesis that SMC proliferation leads to occlusive
lesions.
ACTA2mutations associated with MMD provide further
evidence that early-onset strokes may occur via a similar
pathway of excessive SMC proliferation leading to arterial
occlusion. MMD is a speciﬁc cerebrovascular disease char-
acterized by stenosis or occlusion of the terminal portions
of the internal carotid arteries and the formation of an
abnormal vascular network in the vicinity of the arterial
occlusion. The etiology of MMD is not understood, but it
is established that genetic factors play a role, given that
6%–12% of MMD cases are familial.24,25 Histopathologic
studies of the involved internal carotid arteries show ﬁbro-
cellular proliferation of intimal SMCs as the cause of the
arterial occlusion.26 Therefore, the MMD vascular lesions
demonstrate the same increased SMC proliferation as
observed in the ACTA2 vascular lesions.
The increased proliferation observed in ACTA2-mutant
SMCs may be due to the role that a-actin polymerization
plays in modulating the SMC phenotype between a quies-
cent cell expressing high levels of contractile and cytoskel-
etal proteins and a proliferating cell not expressing
contractile proteins.7,27 We have previously demonstrated
that the ACTA2 missense mutations lead to decreased SM
a-actin polymerization into ﬁlaments in SMCs, suggesting
a dominant-negative effect of the mutant a-actin on actin-
ﬁlament formation by disruption of polymerization of
monomeric a-actin (G-actin) into polymerized (F-actin)The Amactin.10 It is already established that when F-actin polymer-
ization is inhibited, leading to an increased concentration
of free G-actin, a signal is transduced to the nucleus and
MRTF-A and MRTF-B are translocated from the nucleus
into the cytosol. In the nucleus, these proteins form
a complex with serum response factor (SRF) and myocar-
din and drive expression of SMC contractile genes. Thus,
the nuclear export of MRTF-A/B leads to downregulation
of contractile protein expression. Furthermore, reduction
of nuclear MRTF-A/B allows ternary complex factors
(TCFs, members of the Ets family of transcription factors)
to bind to SRF because MRTFs and TCFs compete for
binding to a common surface of SRF.28,29 The TCF-SRF
complex activates a subset of SRF-regulated growth-
responsive genes, leading to cellular proliferation.
Despite the presence of mutant SM a-actin in all vascular
SMCs, pathology and clinical imaging in patients suggest
that SMC proliferation occurs in localized regions of the
arteries. Histologic examination of ACTA2-mutant aortas
documents that a subset of the vasa vasorum arteries are
occluded as a result of SMC proliferation. In addition, the
imaging from the patients with Moyamoya disease and
ACTA2 p.R258C/H mutations demonstrates occlusion of
a discrete region of the internal carotid artery. Therefore,
we hypothesize that the SMC proliferation leading to arte-
rial occlusion is dependent on the presence of the muta-
tion and an additional factor, most likely vascular injury
or increased biomechanical stress.
ACTA2 mutations lead to dilatation of the aorta but
occlusion of smaller arteries, and this differential response
to an underlying defect in SM a-actin may be due to
a number of factors. First, the aorta and many of its large
arterial branches are elastic arteries, in which the media
is composed of SMCs lying between layers of elastic ﬁbers.
In contrast, medium and small arteries are muscular
arteries, in which the SMC are attached to each other
and not layers of elastic ﬁbers.30 Elastin has an established
role in increasing SMC differentiation and decreasing SMC
proliferation, and the lack of SMC and elastic-ﬁber interac-
tion may increase proliferation in muscular arteries.31
Second, the ascending aorta bears the majority of the force
of the pulsatile blood as it is ejected from the contracting
heart, whereas other arteries experience signiﬁcantly less
force from blood ﬂow. The physiological forces may acti-
vate different pathways in the mutant SMCs, leading to
different vascular disease presentation. In addition,
different lineage origins of vascular SMCs may contribute
to the differing vascular diseases. The ascending aortic-
and cerebral-vessel SMCs are neural crest derived, whereas
other vascular SMCs are mesoderm derived.32
The identiﬁcation of ACTA2 mutations as causes of
TAAD, premature CAD, and stroke put forth the concept
that a mutation in a single gene can cause a variety of
vascular diseases, as opposed to a single type of vascular
disease, within a family. Recent genome-wide association
studies also support this concept through the identiﬁca-
tion of single-nucleotide polymorphisms on chromosomeerican Journal of Human Genetics 84, 617–627, May 15, 2009 625
9p21 associated with a variety of vascular diseases,
including CAD, abdominal aortic aneurysm, and cerebral
aneurysms.33 Current studies for the identiﬁcation of
genes leading to vascular diseases focus on families with
multiple members with a particular vascular disease, such
as CAD or ischemic stroke, and the data presented here
should modify these studies. Our data also has clinical
implications for determining the risk for vascular disease
on the basis of family history. Additionally, the clinical
management of patients harboring ACTA2 mutations
should be modiﬁed on the basis of these data. In addition
to the currently recommended routine imaging of the
aorta for aneurysms, ACTA2-mutation carriers should be
monitored for CAD and occlusive cerebrovascular disease.
Finally, inappropriate proliferation of SMCs as a result of
an ACTA2 mutation may represent a novel pathogenetic
pathway contributing to occlusive vascular disease.
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